Braco-19

Category	Cytomegalovirus (CMV)
CAS	351351-75-2
Description	Braco-19 is a potent telomerase/telomere inhibitor that prevents telomerase catalysis. Braco-19, as a G-quadruplex (GQ) binding ligand, stabilizes GQ formation at 3V telomeric DNA overhang and produces rapid senescence or selective cell death. It is also an HAdV virus replication inhibitor.

Quotation Now

Product Information

Synonyms	N-(9-{[4-(dimethylamino)phenyl]amino}-6-[3-(pyrrolidin-1-yl)propanamido]acridin-3-yl)-3-(pyrrolidin-1-yl)propanamide; N,N'-[9[[4-(Dimethylamino)phenyl]amino]-3,6-acridinediyl]bis-1-pyrrolidinepropanamide; 9-[4-(N,N-dimethylamino)phenylamino]-3,6-bis(3-pyrrolodinopropionamido)acridine
IUPAC Name	N-[9-[4-(dimethylamino)anilino]-6-(3-pyrrolidin-1-ylpropanoylamino)acridin-3-yl]-3-pyrrolidin-1-ylpropanamide
Molecular Weight	593.76
Molecular Formula	C35H43N7O2
Canonical SMILES	CN(C)C1=CC=C(C=C1)NC2=C3C=CC(=CC3=NC4=C2C=CC(=C4)NC(=O)CCN5CCCC5)NC(=O)CCN6CCCC6
InChI	InChI=1S/C35H43N7O2/c1-40(2)28-11-7-25(8-12-28)38-35-29-13-9-26(36-33(43)15-21-41-17-3-4-18-41)23-31(29)39-32-24-27(10-14-30(32)35)37-34(44)16-22-42-19-5-6-20-42/h7-14,23-24H,3-6,15-22H2,1-2H3,(H,36,43)(H,37,44)(H,38,39)
InChIKey	RKPYSYRMIXRZJT-UHFFFAOYSA-N
Boiling Point	855.0±65.0°C at 760 mmHg
Flash Point	470.857°C
Purity	≥95%
Density	1.3±0.1 g/cm3
Solubility	Soluble in DMSO
Appearance	Solid Powder
Application	Cytostatic Agents
Storage	Store at 2-8°C for short term (days to weeks) or -20°C for long term (months to years)
Complexity	870
Exact Mass	593.34782364
Index Of Refraction	1.708
In Vitro	Braco-19, as a well-known GQ binding ligand, interacts specifically with hadvgqs, increasing its stability and preventing the proliferation of HAdV. BRACO-19 (1.0-10 μM; 5d) has no growth inhibition effect on UXF1138L cells, and its IC50 is 2.5 μM and IC100 is 5 μM. BRACO-19(1 μM; 24 hours) showed a significant decrease in nuclear hTERT expression. However, residual cytoplasmic hTERT staining is accompanied by the occurrence of atypical mitosis. BRACO-19(0-40 μM; 24 h) reduces the growth of AdV virus in eGFP transfected hek293 cells in a dose-dependent manner.
In Vivo	BRACO-19 administration, QDX5 is effective in inhibiting tumor growth in early xenograft, but ineffective for advanced xeneugraft. BRACO-19 (intraperitoneal injection; 2mg/kg; 3 weeks; Beginning 6 days after transplantation of UXF1138LX fragments) significantly inhibited tumor growth, and under these conditions, significant single-dose antitumor activity was observed, and some animals in this group showed complete regression (5 out of 12 tumors).
PSA	103.05000
Target	CMV; DNA/RNA Synthesis
XLogP3-AA	4.5